Hondo (@JimTom44) header
Hondo (@JimTom44) profile picture
Joined September 2014
Photo by Hondo (@JimTom44)Photo by Hondo (@JimTom44)Photo by Hondo (@JimTom44)Photo by Hondo (@JimTom44)Photo by Hondo (@JimTom44)Photo by Hondo (@JimTom44)Photo by Hondo (@JimTom44)Photo by Hondo (@JimTom44)Photo by Hondo (@JimTom44)Photo by Hondo (@JimTom44)
Is $RDGL flying under the radar? With Mayo's RadioGel study advancing through the IRB's final review process, important milestones are getting closer. First patient dosing, clinical data, IsoPet revenue growth and PrecisionGel represent multiple potential drivers ahead. The current share price doesn't tell the whole story. For investors willing to look beyond today's trading, RDGL deserves a closer look. The next chapters could be very interesting. $RDGL #Biotech #CancerResearch #MicroCap #Investing
1
2
14
337
$rdgl Awesome news and I'm sure Bauer's parents are happy to see their baby feeling better and with his life extended.
"One of the really wonderful and important things in his case is that the possibility of treating him with a single treatment also allowed us to avoid increasing the risk of complications related to his other medical conditions. " - Dr. Sanchez, Oncologist at NorthStarVETS $RDGL
4
18
309
Meet Major! 1 year after treatment and no signs of recurrence! His case study titled Adjuvant Interstitial Yttrium-90 Hydrogel (IsoPet®) Following Limb-Sparing Marginal Excision of Multifocal Distal Pelvic-Limb Neoplasia in a Dog is available on our websites!
1
2
12
357
$rdgl Twenty in one week is impressive. And to think it could be hundred(s) weekly in the not so distant future. @IsoPetForCancer must be close to 300 total treatments so far?
Team IsoPet celebrates a record breaking week as 20 pets are scheduled to receive PRnT cancer treatments this week! This milestone reflects growing adoption, commercial momentum and our commitment to giving more pets a new chance in the fight against cancer. $RDGL
4
17
357
$rdgl @VivosIncUSA Great news for Percy and all animals that may need this treatment. @IsoPetForCancer licensed clinics have treated more than 200 animals.
Meet Percy who received IsoPet Precision Radionuclide Therapy at Sun City Veterinary Surgery Center in El Paso, TX. His remarkable progress shows the promise of targeted cancer therapy and brings hope to pets and the families who love them. $RDGL
1
13
197
Replying to @1amgme
$RDGL PrecisionGel’s potential is genuinely mind-boggling for localized healthcare.
1
8
329
$rdgl. #cancer Excellent description.
$RDGL RadioGel for humans and IsoPet for animals. Same device two different markets. The Gel without the Yttrium90 is PrecisionGel. Adding proteins or other drugs makes it a complete new device for immunotherapy or other treatments. You see the potential ?
2
11
286
$rdgl. CEO Dr. Michael Korenko buys 200,000 more shares. sec.gov/Archives/edgar/data/…
1
1
13
551
Vivos is building momentum! Our Business Strategy Advisory Board aligned on key actions to complete our current development phase and prepare for our next major business phase. Stay tuned for our September business update later today highlighting progress! $RDGL
4
13
374
$rdgl @VivosIncUSA @BradWeeks0331 Great points and so true. The device has saved 200+ limbs and/or lives of animals so we know it works. Time to do the same in humans via the FDA approved human trials with Mayo clinic. It takes time and patience of Jobe but will be worth it.
$RDGL is getting closer to the point where the story can change quickly. The Mayo IRB process is in Mayo’s hands and advancing. We've already had a sneak peek at the potential through 200+ animal treatments and human experience from the India studies. Now comes Mayo, first patient, and U.S. clinical data. At roughly $0.05/share, the current valuation leaves plenty of room for a major revaluation if the clinical story continues to develop positively. Just as an illustrative scenario, $0.10, $0.20 or even $0.50 would represent significant appreciation from current levels. Not price targets, just showing what a changing valuation could look like as milestones and data reduce uncertainty. 💹 IRB → First Patient → Clinical Data → Validation → Potential Revaluation The setup is getting very interesting. 🔥 $RDGL #RadioGel #Biotech #Cancer #Investing
8
16
551
With the recent FDA approval to initiate clinical trials, RadioGel® is advancing the treatment of metastatic tumors while preserving voice, swallowing function, and critical neck anatomy—outcomes that could make a profound difference for patients. $RDGL
1
5
17
1,094
$rdgl @RadioGel @BradWeeks0331 If Vivos' medical partners see huge potential here for non-resectable metastatic papillary thyroid cancer in the neck where repeat surgery carries significant risks and good alternatives are limited, imagine what they will see with these cancers:
1
4
17
575
Our medical partners see huge potential here for non-resectable metastatic papillary thyroid cancer in the neck where repeat surgery carries significant risks and good alternatives are limited. This targeted Y-90 hydrogel offers a major improvement over what's currently available: destroying tumors while protecting critical structures. America leads in precision cancer innovation. Proud to partner on breakthroughs that give patients better options! 🇺🇸 $RDGL
9
680
$rdgl "The Mayo Clinic clinical team has reviewed the protocol, expressed support for the study and voted to proceed. Mayo Clinic collaborators have confirmed that the study is progressing through the institution’s established process as quickly as reasonably possible."
4
18
387
Great progress news... also frustrating because the medical industry as a whole, FDA, etc., just red tapes itself into corners. It is absolutely ridiculous the number of "eyes" needed to review this, review that... absurd.
6
497
$rdgl @VivosIncUSA 29 questions and 29 thorough answers. Thank you Dr. Korenko for the transparency and answering so many or the questions shareholders were asking. You and the team you put together are seeing the results of years of hard work. vivosinc.com/investor-relati…
1
4
18
533